



February 23, 2016

ENGROSSED HOUSE BILL No. 1272

DIGEST OF HB 1272 (Updated February 18, 2016 9:58 am - DI 84)

Citations Affected: IC 25-1; IC 25-27.5; IC 25-35.6; IC 35-31.5; IC 35-48.

Synopsis: Professional licensing matters. Requires a practitioner to provide the Indiana professional licensing agency (agency) and the practitioner's specific board with certain information concerning continuing education. (Current law requires a practitioner to provide the information to a specific board.) Allows an individual who holds a professional or occupational license and is called to active duty to fulfill all continuing education requirements through distance learning. Allows the practitioner's specific board to conduct random audits of license renewals of practitioners required to take continuing education courses. Adds certain substances to the definition of "synthetic drugs". Makes the small business member of the jobs creation committee a
(Continued next page)

Effective: July 1, 2016.

Zent, Bauer, Davisson, Bacon

(SENATE SPONSORS — BROWN L, RANDOLPH LONNIE M)

January 11, 2016, read first time and referred to Committee on Public Health.
January 21, 2016, amended, reported — Do Pass.
January 25, 2016, read second time, amended, ordered engrossed.
January 26, 2016, engrossed. Read third time, passed. Yeas 95, nays 0.

SENATE ACTION

February 8, 2016, read first time and referred to Committee on Commerce & Technology.
February 22, 2016, reported favorably — Do Pass.

EH 1272—LS 6628/DI 109



Digest Continued

voting member. Removes the requirement that the physician assistant's supervisory agreement specify each name or drug classification being delegated to the physician assistant. Makes changes to the speech-language pathology and audiology board concerning the date a chairperson is selected. Provides that an employee of the agency must keep information concerning a complaint regarding a regulated occupation confidential unless disclosure is required under law, required for the advancement of an investigation, or made to a law enforcement agency that has jurisdiction or is reasonably believed to have jurisdiction over a person or matter involved in the complaint.



February 23, 2016

Second Regular Session of the 119th General Assembly (2016)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2015 Regular Session of the General Assembly.

ENGROSSED HOUSE BILL No. 1272

A BILL FOR AN ACT to amend the Indiana Code concerning professions and occupations.

Be it enacted by the General Assembly of the State of Indiana:

1 SECTION 1. IC 25-1-4-3, AS AMENDED BY P.L.157-2006,
2 SECTION 13, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3 JULY 1, 2016]: Sec. 3. (a) Notwithstanding any other law, a board that
4 is specifically authorized or mandated to require continuing education
5 as a condition to renew a registration, certification, or license must
6 require a practitioner to comply with the following renewal
7 requirements:

8 (1) The practitioner shall provide the board **and agency**
9 **(established by IC 25-1-5-3)** with a sworn statement executed by
10 the practitioner that the practitioner has fulfilled the continuing
11 education requirements required by the board.

12 (2) The practitioner shall retain copies of certificates of
13 completion for continuing education courses for three (3) years
14 from the end of the licensing period for which the continuing
15 education applied. The practitioner shall provide the board **and**
16 **agency (established by IC 25-1-5-3)** with copies of the
17 certificates of completion upon the board's request for a

EH 1272—LS 6628/DI 109



1 compliance audit.

2 (b) Following every license renewal period, the **agency with**
 3 **consultation from the board shall may** randomly audit for compliance
 4 more than one percent (1%) but less than ten percent (10%) of the
 5 practitioners required to take continuing education courses.

6 SECTION 2. IC 25-1-4-3.2, AS AMENDED BY P.L.2-2008,
 7 SECTION 55, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 8 JULY 1, 2016]: Sec. 3.2. **(a)** A board or agency regulating a profession
 9 or occupation under this title or under IC 16 or IC 22 shall require that
 10 at least one-half (1/2) of all continuing education requirements must be
 11 allowed by distance learning methods, except for doctors, nurses,
 12 chiropractors, optometrists, and dentists.

13 **(b) An individual who is called to active duty (as defined by**
 14 **IC 25-1-12-2) must be allowed to fulfill all continuing education**
 15 **requirements for professional or occupational licenses**
 16 **administered through the Indiana professional licensing agency by**
 17 **distance learning methods.**

18 SECTION 3. IC 25-1-7-10, AS AMENDED BY P.L.227-2015,
 19 SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 20 JULY 1, 2016]: Sec. 10. (a) Except as provided in section 3(b) or 3(c)
 21 of this chapter, all complaints and information pertaining to the
 22 complaints shall be held in strict confidence until the attorney general
 23 files notice with the board of the attorney general's intent to prosecute
 24 the licensee.

25 (b) A person in the employ of the office of attorney general, ~~or any~~
 26 ~~of the boards,~~ **the Indiana professional licensing agency,** or any
 27 person not a party to the complaint may not disclose or further a
 28 disclosure of information concerning the complaint unless the
 29 disclosure is:

- 30 (1) required under law;
 31 (2) required for the advancement of an investigation; or
 32 (3) made to a law enforcement agency that has jurisdiction or is
 33 reasonably believed to have jurisdiction over a person or matter
 34 involved in the complaint.

35 SECTION 4. IC 25-1-16-7, AS AMENDED BY P.L.112-2014,
 36 SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 37 JULY 1, 2016]: Sec. 7. (a) The committee consists of the following
 38 individuals:

- 39 (1) The executive director of the agency or the executive director's
 40 designee. The executive director or the executive director's
 41 designee shall serve as chairperson of the committee.
 42 (2) The director of the office or the director's designee.



- 1 (3) The attorney general or the attorney general's designee, as a
 2 nonvoting member.
- 3 (4) An individual appointed by the governor who represents an
 4 association that has small businesses, small business owners, or
 5 licensed professionals as a majority of its members. ~~as a~~
 6 ~~nonvoting member~~. The member serves at the pleasure of the
 7 governor.
- 8 (5) Two (2) individuals appointed by the governor who are
 9 licensed in a regulated occupation.
- 10 (6) Two (2) individuals appointed by the governor who are not
 11 licensed in a regulated occupation.
- 12 (b) The term of a member appointed under subsection (a)(5) or
 13 (a)(6) is three (3) years.
- 14 (c) The affirmative votes of a majority of the voting members
 15 appointed to the committee are required for the committee to take
 16 action on any measure.
- 17 (d) Notwithstanding any other law, the term of a member appointed
 18 before July 1, 2014, under subsection (a)(5) or (a)(6) expires on July 1,
 19 2014.
- 20 SECTION 5. IC 25-27.5-5-2, AS AMENDED BY P.L.197-2011,
 21 SECTION 120, IS AMENDED TO READ AS FOLLOWS
 22 [EFFECTIVE JULY 1, 2016]: Sec. 2. (a) A physician assistant must
 23 engage in a dependent practice with physician supervision. A physician
 24 assistant may perform, under the supervision of the supervising
 25 physician, the duties and responsibilities that are delegated by the
 26 supervising physician and that are within the supervising physician's
 27 scope of practice, including prescribing and dispensing drugs and
 28 medical devices. A patient may elect to be seen, examined, and treated
 29 by the supervising physician.
- 30 (b) If a physician assistant determines that a patient needs to be
 31 examined by a physician, the physician assistant shall immediately
 32 notify the supervising physician or physician designee.
- 33 (c) If a physician assistant notifies the supervising physician that the
 34 physician should examine a patient, the supervising physician shall:
- 35 (1) schedule an examination of the patient in a timely manner
 36 unless the patient declines; or
- 37 (2) arrange for another physician to examine the patient.
- 38 (d) If a patient is subsequently examined by the supervising
 39 physician or another physician because of circumstances described in
 40 subsection (b) or (c), the visit must be considered as part of the same
 41 encounter except for in the instance of a medically appropriate referral.
- 42 (e) A supervising physician or physician assistant who does not



1 comply with subsections (b) through (d) is subject to discipline under
2 IC 25-1-9.

3 (f) A physician assistant's supervisory agreement with a supervising
4 physician must:

5 (1) be in writing;

6 (2) include all the tasks delegated to the physician assistant by the
7 supervising physician;

8 (3) set forth the supervisory plans for the physician assistant,
9 including the emergency procedures that the physician assistant
10 must follow; and

11 (4) specify the ~~name of the drug or drug classification being~~
12 ~~delegated to the physician assistant and the protocol the physician~~
13 ~~assistant shall follow in prescribing a drug.~~

14 (g) The physician shall submit the supervisory agreement to the
15 board. The physician assistant may prescribe a drug under the
16 supervisory agreement unless the board denies the supervisory
17 agreement. Any amendment to the supervisory agreement must be
18 resubmitted to the board, and the physician assistant may operate under
19 any new prescriptive authority under the amended supervisory
20 agreement unless the agreement has been denied by the board.

21 (h) A physician or a physician assistant who violates the supervisory
22 agreement described in this section may be disciplined under
23 IC 25-1-9.

24 SECTION 6. IC 25-35.6-2-1 IS AMENDED TO READ AS
25 FOLLOWS [EFFECTIVE JULY 1, 2016]: Sec. 1. (a) There is
26 established the speech-language pathology and audiology board.

27 (b) The board shall be comprised of six (6) members, who shall be
28 appointed by the governor. Five (5) board members shall have been
29 residents of this state for at least one (1) year immediately preceding
30 their appointment and shall have been engaged in rendering services
31 to the public, teaching, or research in speech-language pathology or
32 audiology for at least five (5) years immediately preceding their
33 appointment. At least two (2) board members shall be speech-language
34 pathologists and at least two (2) shall be audiologists, with the fifth
35 member being either a speech-language pathologist or audiologist. At
36 least one (1) of these five (5) members must be engaged in an active
37 private practice of speech-language pathology or audiology. The sixth
38 member of the board, to represent the general public, shall be a resident
39 of this state who has never been associated with speech-language
40 pathology or audiology in any way other than as a consumer. Except for
41 the member representing the general public, all board members shall
42 at all times be holders of active and valid licenses for the practice of



1 speech-language pathology or audiology in this state.

2 (c) The governor shall also appoint one (1) nonvoting advisor, who
3 must be a licensed physician and board certified in otolaryngology, to
4 serve a four (4) year term of office on the board.

5 (d) Appointments shall be for three (3) year terms, with no person
6 being eligible to serve more than two (2) full consecutive terms. Terms
7 shall begin on the first day of the calendar year and end on the last day
8 of the calendar year, except for the first appointed members, who shall
9 serve through the last calendar day of the year in which they are
10 appointed before commencing the terms prescribed by this subsection.
11 Any member of the board may serve until the member's successor is
12 appointed and qualified under this chapter.

13 (e) The governor may consider, but shall not be bound to accept,
14 recommendations for board membership made by a statewide
15 association for speech-language and hearing. A statewide association
16 for speech-language and hearing may submit to the governor its
17 recommendations for board membership not less than sixty (60) days
18 before the end of each calendar year. In the event of a mid-term
19 vacancy, such association may make recommendations for filling such
20 vacancy.

21 (f) ~~The board shall meet during the first month of each calendar year~~
22 ~~to select a chairman and for other appropriate purposes. At least one (1)~~
23 ~~additional meeting shall be held before the end of each calendar year.~~
24 **At the first meeting of the board each year, members shall elect a**
25 **chairperson for the subsequent twelve (12) month period.** Further
26 meetings may be convened at the call of the ~~chairman~~ **chairperson** or
27 the written request of any two (2) board members. All meetings of the
28 board shall be open to the public, except that the board may hold closed
29 sessions to prepare, approve, grade, or administer examinations or,
30 upon request of an applicant who fails an examination, to prepare a
31 response indicating any reason for ~~his~~ **the applicant's** failure. All
32 meetings of the board must be held in Indiana.

33 (g) Four (4) members of the board constitute a quorum. A majority
34 of the quorum may transact business.

35 SECTION 7. IC 35-31.5-2-321, AS AMENDED BY P.L.196-2013,
36 SECTION 16, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
37 JULY 1, 2016]: Sec. 321. "Synthetic drug" means:

38 (1) a substance containing one (1) or more of the following
39 chemical compounds, including an analog of the compound:

40 (A) JWH-015 ((2-Methyl-1-propyl-1H-
41 indol-3-yl)-1-naphthalenylmethanone).

42 (B) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).

EH 1272—LS 6628/DI 109



- 1 (C) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).
 2 (D) JWH-073
 3 (naphthalen-1-yl-(1-butylindol-3-yl)methanone).
 4 (E) JWH-081 (4-methoxynaphthalen-1-yl-(1-pentylindol-
 5 3-yl)methanone).
 6 (F) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
 7 (G) JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)-
 8 naphthalen-1-yl-methanone).
 9 (H) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).
 10 (I) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).
 11 (J) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).
 12 (K) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-
 13 3-(2-methyloctan-2-yl)-
 14 6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol).
 15 (L) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-
 16 3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo
 17 [c]chromen-1-ol).
 18 (M) HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-
 19 (2-methyloctan-2-yl)phenyl]-
 20 7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
 21 (N) HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6-
 22 (1-methylethenyl)-2-cyclohexen-1-yl]-5
 23 -pentyl-2,5-cyclohexadiene-1,4-dione).
 24 (O) CP 55,940
 25 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-
 26 5-(2-methyloctan-2-yl)phenol).
 27 (P) CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]-5-
 28 (2-methyloctan-2-yl)phenol) and its homologues, or
 29 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)
 30 phenol, where side chain n=5, and homologues where side
 31 chain n=4, 6, or 7.
 32 (Q) WIN 55212-2
 33 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
 34 pyrrolo [1,2,3-de)-1,4-benzoxazin-
 35 6-yl]-1-naphthalenylmethanone).
 36 (R) RCS-4 ((4-methoxyphenyl)
 37 (1-pentyl-1H-indol-3-yl)methanone).
 38 (S) RCS-8 (1-(1-(2-cyclohexylethyl)-1H-
 39 indol-3-yl)-2-(2-methoxyphenyl)ethanone).
 40 (T) 4-Methylmethcathinone. Other name: mephedrone.
 41 (U) 3,4-Methylenedioxymethcathinone. Other name:
 42 methylone.



1	(V) Fluoromethcathinone.
2	(W) 4-Methoxymethcathinone. Other name: methedrone.
3	(X) 4-Ethylmethcathinone (4-EMC).
4	(Y) Methylenedioxypropylvalerone. Other name: MDPV.
5	(Z) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.
6	(AA) JWH-098, or
7	1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.
8	(BB) JWH-164, or
9	1-pentyl-3-(7-methoxy-1-naphthoyl)indole.
10	(CC) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.
11	(DD) JWH-201, or
12	1-pentyl-3-(4-methoxyphenylacetyl)indole.
13	(EE) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.
14	(FF) AM-694, or
15	1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
16	(GG) CP 50,556-1, or
17	[(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylp-
18	ntan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1
19	-yl] acetate.
20	(HH) Dimethylheptylpyran, or DMHP.
21	(II) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP.
22	(JJ) 6-APB [6-(2-aminopropyl)benzofuran].
23	(LL) 7-hydroxymitragynine.
24	(MM) α -PPP [α -pyrrolidinopropiophenone].
25	(NN) α -PVP (desmethylpyrovalerone).
26	(OO) AM-251.
27	(PP) AM-1241.
28	(QQ) AM-2201.
29	(RR) AM-2233.
30	(SS) Buphedrone.
31	(TT) Butylone.
32	(UU) CP-47,497-C7.
33	(VV) CP-47,497-C8.
34	(WW) Desoxypipradol.
35	(XX) Ethylone.
36	(YY) Eutylone.
37	(ZZ) Flephedrone.
38	(AAA) JWH-011.
39	(BBB) JWH-020.
40	(CCC) JWH-022.
41	(DDD) JWH-030.
42	(EEE) JWH-182.



1 (FFF) JWH-302.
 2 (GGG) MDAI [5,6-methylenedioxy-2-aminoindane].
 3 (HHH) Mitragynine.
 4 (III) Naphyrone.
 5 (JJJ) Pentedrone.
 6 (LLL) Pentylone.
 7 (MMM) Methoxetamine
 8 [2-(3-methoxyphenyl)-2-(ethylamino)-cyclohexanone].
 9 (NNN) A796,260 [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-
 10 (2,2,3,3-tetramethylcyclopropyl)methanone].
 11 (OOO) AB-001[(1s,3s)-adamantan-1-yl]
 12 (1-pentyl-1H-indol-3-yl)methanone] or [1-Pentyl-3-
 13 (1-adamantoyl)indole].
 14 (PPP) AM-356 [Methanandamide].
 15 (QQQ) AM 1248 [1-[(1-methyl-2-piperidinyl) methyl]-
 16 1H-indol-3-yl] tricyclo[3.3.1.1^{3,7}] dec-1-yl-methanone]or
 17 [(1-[(N-methylpiperidin-2-yl)
 18 Methyl]-3-(Adamant-1-oyl)indole].
 19 (RRR) AM 2233 Azepane isomer [(2-iodophenyl)
 20 (1-(1-methylazepan-3-yl)-1H-indol-3-yl)methanone].
 21 (SSS) CB-13 [1-Naphthalenyl
 22 [4-(pentyoxy)-1-naphthalenyl]methanone].
 23 (TTT) UR-144 [(1-pentyl-1H-indol-3-yl)
 24 (2,2,3,3-tetramethylcyclopropyl)-methanone].
 25 (UUU) URB 597 [(3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-
 26 cyclohexylcarbamate].
 27 (VVV) URB602 [[1,1'-biphenyl]-3-yl-carbamic acid,
 28 cyclohexyl ester].
 29 (WWW) URB 754 [6-methyl-2-[(4-methylphenyl)
 30 amino]-1-benzoxazin-4-one].
 31 (XXX) XLR-11 or 5-fluoro UR-144
 32 (1-(5-fluoropentyl)-1H-indol-3-yl)
 33 (2,2,3,3-tetramethylcyclopropyl)methanone].
 34 (YYY) AKB48 (Other names include:
 35 N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide;
 36 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-
 37 carboxamide).
 38 (ZZZ) 25I-NBOMe (Other names include:
 39 4-Iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-
 40 benzeneethanamine);
 41 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
 42 methyl]ethanamine).



1 (AAAA) 2C-C-NBOMe (Other names include: 25C-NBOMe;
 2 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
 3 methyl]ethanamine;
 4 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)
 5 phenethylamine).
 6 (BBBB) 2NE-1 (Other names include: 1-Pentyl-3-
 7 (1-adamantylamido)indole).
 8 (CCCC) STS-135 (Other names include:
 9 N-Adamantyl-1-fluoropentylindole-3- carboxamide
 10 (1-5-fluoropentyl)-N-tricyclo[3.3.1.1.3.7]dec-1-yl-1H-
 11 indole-3-carboxamide).
 12 **(DDDD) PB-22 (Other names include:**
 13 **1-Pentyl-8-quinolinyl ester-1H-indole-2-carboxylic acid).**
 14 **(EEEE) 5-Fluoro-PB-22 (Other names include:**
 15 **1-(5-Fluoropentyl)-8-quinolinyl ester 1H-indole-3-carboxylic**
 16 **acid).**
 17 **(FFFF) Benocyclidine (Other names include: BCP, BTCP,**
 18 **and Benzothiophenylcyclohexylpiperidine).**
 19 **(GGGG) 25B-NBOMe (Other names include:**
 20 **2C-B-NBOMe and 4-Bromo-2,**
 21 **5-dimethoxy-N-[(2-Methoxyphenyl)methyl]**
 22 **benzeneethanamine).**
 23 **(HHHH) APB (Other names include; (2-Aminopropyl)**
 24 **Benzofuran).**
 25 **(III) AB-PINACA**
 26 **(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-**
 27 **indazole-3-carboxamide.**
 28 **(JJJJ) AB-FUBINACA**
 29 **(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenz**
 30 **yl)-1H-indazole-3-carboxamide).**
 31 **(KKKK) ADB-PINACA**
 32 **(N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H**
 33 **-indaole-3-carboxamide).**
 34 **(LLLL) Fluoro ADBICA (N-(1-Amino-3,3-**
 35 **dimethyl-1-oxobutan-2-yl)-(fluoropentyl)-1H-indole-3-**
 36 **carboxamide).**
 37 **(MMMM) APDB (Other names include: -EMA,**
 38 **-Desoxy-MDA, and (2-Aminopropyl)-2,3-**
 39 **dihydrobenzofuran).**
 40 **(NNNN) THJ-2201 (Other names include: AM2201**
 41 **indazole analog, Fluoropentyl-JWH-018 indazole, and**
 42 **5-Fluoro-THJ-018).**



- 1 (OOOO) AM 2201 benzimidazole analog (Other names
 2 include: FUBIMINA, FTHJ, and (1-(5-fluoropentyl)-1H-
 3 benzo[d]imidazol-2-yl)(naphthalene-1-yl)methanone).
 4 (PPPP) MN-25 (Other names include: 7-methoxy-1-
 5 [2-(4-morpholinyl)ethyl]-N-[1S, 2S, 4R]-1,3,3-
 6 trimethylbicyclo[2.2.1]hept-2-yl]-1H-indole-3-carboxamide
 7 and UR-12).
 8 (QQQQ) FUB-PB-22 (Other names include:
 9 Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate).
 10 (RRRR) FUD-PB-22 (Other names include:
 11 Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxy-
 12 late).
 13 (SSSS) 5-Fluoro-AB-PINACA (Other names include:
 14 AB-PINACA 5-fluoro analog and N-(1-amino-3-methyl-1-
 15 oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carbox-
 16 amide).
 17 (TTTT) 4-MePPP (Other names include:
 18 4-methyl-alpha-pyrrolidinopropiophenone).
 19 (UUUU) alpha-PBP (Other names include:
 20 Alpha-pyrrolidinobutiophenone).
 21 (VVVV) AB-CHMINACA (Other names include:
 22 (N-[1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylme-
 23 thyl)-1H-indazole-3-carboxamide).
 24 (WWWW) Acetyl fentanyl (Other names include:
 25 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).
 26 (2) Any compound structurally derived from
 27 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by
 28 substitution at the nitrogen atom of the indole ring by alkyl,
 29 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
 30 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
 31 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
 32 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
 33 or not further substituted in the indole ring to any extent and
 34 whether or not substituted in the naphthyl ring to any extent.
 35 (3) Any compound structurally derived from 3-(1-naphthoyl)
 36 pyrrole by substitution at the nitrogen atom of the pyrrole ring by
 37 alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
 38 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
 39 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
 40 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl
 41 group, whether or not further substituted in the pyrrole ring to any
 42 extent and whether or not substituted in the naphthyl ring to any



- 1 extent.
- 2 (4) Any compound structurally derived from
3 1-(1-naphthylmethyl)indene by substitution at the 3-position of
4 the indene ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
5 c y c l o a l k y l m e t h y l , c y c l o a l k y l e t h y l ,
6 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
7 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
8 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
9 or not further substituted in the indene ring to any extent and
10 whether or not substituted in the naphthyl ring to any extent.
- 11 (5) Any compound structurally derived from 3-phenylacetylindole
12 by substitution at the nitrogen atom of the indole ring with alkyl,
13 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
15 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
16 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
17 or not further substituted in the indole ring to any extent and
18 whether or not substituted in the phenyl ring to any extent.
- 19 (6) Any compound structurally derived from
20 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position
21 of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
22 c y c l o a l k y l m e t h y l , c y c l o a l k y l e t h y l ,
23 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
24 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
25 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
26 or not substituted in the cyclohexyl ring to any extent.
- 27 (7) Any compound containing a 3-(benzoyl)indole structure with
28 substitution at the nitrogen atom of the indole ring by alkyl,
29 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
30 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or
31 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
32 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
33 or not further substituted in the indole ring to any extent and
34 whether or not substituted in the phenyl ring to any extent.
- 35 (8) Any compound, except bupropion or a compound listed under
36 a different schedule, structurally derived from
37 2-aminopropan-1-one by substitution at the 1-position with either
38 phenyl, naphthyl, or thiophene ring systems, whether or not the
39 compound is further modified:
- 40 (A) by substitution in the ring system to any extent with alkyl,
41 alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
42 substituents, whether or not further substituted in the ring



- 1 system by one or more other univalent substituents;
2 (B) by substitution at the 3-position with an acyclic alkyl
3 substituent;
4 (C) by substitution at the 2-amino nitrogen atom with alkyl,
5 dialkyl, benzyl, or methoxybenzyl groups; or
6 (D) by inclusion of the 2-amino nitrogen atom in a cyclic
7 structure.
- 8 (9) Any compound structurally derived from 3-tetramethyl
9 cyclopropanoylindole with substitution at the nitrogen atom of the
10 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl,
12 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl) ethyl,
13 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-
14 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether
15 or not further substituted in the indole ring to any extent and
16 whether or not substituted in the tetramethylcyclopropyl ring to
17 any extent.
- 18 (10) Any compound containing a N-(1-adamantyl)-
19 1H-indazole-3-carboxamide structure with substitution at the
20 nitrogen atom of the indazole ring by an alkyl, haloalkyl,
21 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
22 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
23 1-(N-methyl-2-pyrrolidinyl) methyl,
24 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl
25 group, whether or not further substituted at the nitrogen atom of
26 the carboxamide to any extent, whether or not further substituted
27 in the indazole ring to any extent, and whether or not further
28 substituted on the adamantyl ring system to any extent. An
29 example of this structural class includes AKB48.
- 30 (11) Any compound containing a N-(1-adamantyl)-
31 1H-indole-3-carboxamide structure with substitution at the
32 nitrogen atom of the indole ring by an alkyl, haloalkyl,
33 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
34 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
35 1-(N-methyl-2-pyrrolidinyl) methyl,
36 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl
37 group, whether or not further substituted at the nitrogen atom of
38 the carboxamide to any extent, whether or not further substituted
39 in the indole ring to any extent, and whether or not further
40 substituted on the adamantyl ring system to any extent. An
41 example of this structural class includes STS-135.
- 42 (12) Any compound containing a 3-(1-adamantoyl)indole



1 structure with substitution at the nitrogen atom of the indole ring
 2 by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
 3 cycloalkylethyl, 1-(N-methyl-2- piperidinyl)methyl, or
 4 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl,
 5 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl
 6 group, whether or not further substituted on the adamantyl ring
 7 system to any extent. An example of this structural class includes
 8 AM-1248.

9 (13) Any compound determined to be a synthetic drug by rule
 10 adopted under IC 25-26-13-4.1.

11 SECTION 8. IC 35-48-2-4, AS AMENDED BY P.L.283-2013,
 12 SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 13 JULY 1, 2016]: Sec. 4. (a) The controlled substances listed in this
 14 section are included in schedule I.

15 (b) Opiates. Any of the following opiates, including their isomers,
 16 esters, ethers, salts, and salts of isomers, esters, and ethers, unless
 17 specifically excepted by rule of the board or unless listed in another
 18 schedule, whenever the existence of these isomers, esters, ethers, and
 19 salts is possible within the specific chemical designation:

20 Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
 21 piperidinyl]-N-phenylacetamide) (9815)
 22 Acetylmethadol (9601)
 23 Allylprodine (9602)
 24 Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
 25 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) (9832)
 26 Alphacetylmethadol (9603)
 27 Alphameprodine (9604)
 28 Alphamethadol (9605)
 29 Alphamethylfentanyl (9814)
 30 Benzethidine (9606)
 31 Beta-hydroxy-3-methylfentanyl (9831). Other name:
 32 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl
 33]-N-phenylpropanamide
 34 Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
 35 phenethyl)-4-piperidinyl]-N-phenylpropanamide) (9830)
 36 Betacetylmethadol (9607)
 37 Betameprodine (9608)
 38 Betamethadol (9609)
 39 Betaprodine (9611)
 40 Clonitazene (9612)
 41 Dextromoramide (9613)
 42 Diampromide (9615)



1	Diethylthiambutene (9616)
2	Difenoxin (9168)
3	Dimenoxadol (9617)
4	Dimepheptanol (9618)
5	Dimethylthiambutene (9619)
6	Dioxaphetyl butyrate (9621)
7	Dipipanone (9622)
8	Ethylmethylthiambutene (9623)
9	Etonitazene (9624)
10	Etoxidine (9625)
11	Furethidine (9626)
12	Hydroxypethidine (9627)
13	Ketobemidone (9628)
14	Levomoramide (9629)
15	Levophenacymorphan (9631)
16	3-Methylfentanyl [N-[3-methyl-1-(2-phenylethyl)-4-
17	piperidyl]-N-phenylpropanamide](9813)
18	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-
19	piperidinyl]-N-phenylpropanamide) (9833)
20	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) (9961)
21	Morpheridine (9632)
22	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl),
23	including any isomers, salts, or salts of isomers (9818)
24	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
25	(thenylfentanyl), including any isomers, salts, or salts of isomers
26	(9834)
27	Noracymethadol (9633)
28	Norlevorphanol (9634)
29	Normethadone (9635)
30	Norpipanone (9636)
31	Para-fluorofentanyl (N-(4-fluorophenyl)-N-
32	[1-(2-phenethyl)-4-piperidinyl] propanamide (9812)
33	Phenadoxone (9637)
34	Phenampramide (9638)
35	Phenomorphane (9647)
36	Phenoperidine (9641)
37	PEPAP [1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine] (9663)
38	Piritramide (9642)
39	Proheptazine (9643)
40	Properidine (9644)
41	Propiram (9649)
42	Racemoramide (9645)



- 1 Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
2 piperidinyl]-propanamide) (9835)
3 Tilidine (9750)
4 Trimeperidine (9646)
- 5 (c) Opium derivatives. Any of the following opium derivatives, their
6 salts, isomers, and salts of isomers, unless specifically excepted by rule
7 of the board or unless listed in another schedule, whenever the
8 existence of these salts, isomers, and salts of isomers is possible within
9 the specific chemical designation:
- 10 Acetorphine (9319)
11 Acetyldihydrocodeine (9051)
12 Benzylmorphine (9052)
13 Codeine methylbromide (9070)
14 Codeine-N-Oxide (9053)
15 Cyprenorphine (9054)
16 Desomorphine (9055)
17 Dihydromorphine (9145)
18 Drotebanol (9335)
19 Etorphine (except hydrochloride salt) (9056)
20 Heroin (9200)
21 Hydromorphanol (9301)
22 Methyldesorphine (9302)
23 Methyldihydromorphine (9304)
24 Morphine methylbromide (9305)
25 Morphine methylsulfonate (9306)
26 Morphine-N-Oxide (9307)
27 Myrophine (9308)
28 Nicocodeine (9309)
29 Nicomorphine (9312)
30 Normorphine (9313)
31 Pholcodine (9314)
32 Thebacon (9315)
- 33 (d) Hallucinogenic substances. Unless specifically excepted or
34 unless listed in another schedule, any material, compound, mixture, or
35 preparation which contains any quantity of the following
36 hallucinogenic, psychedelic, or psychogenic substances, their salts,
37 isomers, and salts of isomers whenever the existence of these salts,
38 isomers, and salts of isomers is possible within the specific chemical
39 designation (for purposes of this subsection only, the term "isomer"
40 includes the optical, position, and geometric isomers):
- 41 (1) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (7473). Other name:
42 TCPy.



- 1 (2) 4-Bromo-2, 5-Dimethoxyamphetamine (7391). Some trade or
 2 other names: 4-Bromo-2, 5-Dimethoxy-a-methylphenethylamine;
 3 4-Bromo-2, 5-DMA.
 4 (3) 4-Bromo-2, 5-dimethoxyphenethylamine (7392). Some trade
 5 or other names:
 6 2-[4-bromo-2,5-dimethoxyphenyl]-1-aminoethane;
 7 alpha-desmethyl DOB; 2C-B, Nexus.
 8 (4) 2, 5-Dimethoxy-4-ethylamphet-amine (7399). Other name:
 9 DOET.
 10 (5) 2, 5-Dimethoxy-4-(n)-propylthiophenethylamine (7348).
 11 Other name: 2C-T-7.
 12 (6) 2, 5-Dimethoxyamphetamine (7396). Some trade or other
 13 names: 2, 5-Dimethoxy-a-methylphenethylamine; 2, 5-DMA.
 14 (7) 4-Methoxyamphetamine (7411). Some trade or other names:
 15 4-Methoxy-a-methylphenethylamine; Paramethoxyamphetamine;
 16 PMA.
 17 (8) 5-Methoxy-3, 4-methylenedioxy amphetamine (7401). Other
 18 Name: MDMA.
 19 (9) 5-Methoxy-N, N-diisopropyltryptamine, including any
 20 isomers, salts, or salts of isomers (7439). Other name:
 21 5-MeO-DIPT.
 22 (10) 4-methyl-2, 5-dimethoxyamphetamine (7395). Some trade
 23 and other names: 4-methyl-2,
 24 5-dimethoxy-a-methylphenethylamine; DOM; and STP.
 25 (11) 3, 4-methylenedioxy amphetamine (7400). Other name:
 26 MDA.
 27 (12) 3,4-methylenedioxy-N-ethylamphetamine (7404). Other
 28 names: N-ethyl-alpha-methyl-3,4(methylenedioxy)
 29 phenethylamine; N-ethyl MDA; MDE; and MDEA.
 30 (13) 3, 4-methylenedioxymethamphetamine (MDMA) (7405).
 31 (14) 3, 4, 5-trimethoxy amphetamine (7390). Other name: TMA.
 32 (15) Alpha-ethyltryptamine (7249). Some trade and other names:
 33 Etryptamine; Monase; [alpha]-ethyl-1H-indole-3-ethanamine;
 34 3-(2-aminobutyl) indole; [alpha]-ET; and AET.
 35 (16) Alpha-methyltryptamine (7432). Other name: AMT.
 36 (17) Bufotenine (7433). Some trade and other names:
 37 3-(B-Dimethylaminoethyl)-5-hydroxyindole;
 38 3-(2-dimethylaminonethyl)-5-indolol; N, N-dimethylserotonin;
 39 5-hydroxy-N, N-dimethyltryptamine; mappine.
 40 (18) Diethyltryptamine (7434). Some trade or other names: N,
 41 N-Diethyltryptamine; DET.
 42 (19) Dimethyltryptamine (7435). Some trade or other names:



- 1 DMT.
- 2 (20) Ibogaine (7260). Some trade and other names: 7-Ethyl-6, 6b,
3 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-pyrido
4 (1', 2': 1, 2, azepino 4, 5-b) indole; tabernanthe iboga.
- 5 (21) Lysergic acid diethylamide (7315). Other name: LSD.
- 6 (22) Marijuana (7360).
- 7 (23) Mescaline (7381).
- 8 (24) Parahexyl (7374). Some trade or other names:
9 3-Hexyl-1-hydroxy-7, 8, 9, 10-Tetrahydro-6, 6,
10 9-trimethyl-6H-dibenzo (b,d) pyran; Snyhexyl.
- 11 (25) Peyote (7415), including:
- 12 (A) all parts of the plant that are classified botanically as
13 lophophora williamsii lemaire, whether growing or not;
- 14 (B) the seeds thereof;
- 15 (C) any extract from any part of the plant; and
- 16 (D) every compound, manufacture, salt, derivative, mixture, or
17 preparation of the plant, its seeds, or extracts.
- 18 (26) N-ethyl-3-piperidyl benzilate (7482). Other name: DMZ.
- 19 (27) N-hydroxy-3,4-methylenedioxyamphetamine (7402). Other
20 names: N-hydroxy-alpha-methyl-3,4
21 (methylenedioxy)phenethylamine; and N-hydroxy MDA.
- 22 (28) N-methyl-3-piperidyl benzilate (7484). Other name: LBJ.
- 23 (29) Psilocybin (7437).
- 24 (30) Psilocyn (7438).
- 25 (31) Tetrahydrocannabinols (7370), including synthetic
26 equivalents of the substances contained in the plant, or in the
27 resinous extractives of Cannabis, sp. and synthetic substances,
28 derivatives, and their isomers with similar chemical structure and
29 pharmacological activity such as:
- 30 (A) π^1 cis or trans tetrahydrocannabinol, and their optical
31 isomers;
- 32 (B) π^6 cis or trans tetrahydrocannabinol, and their optical
33 isomers; and
- 34 (C) $\pi^{3,4}$ cis or trans tetrahydrocannabinol, and their optical
35 isomers.
- 36 Since nomenclature of these substances is not internationally
37 standardized, compounds of these structures, regardless of
38 numerical designation of atomic positions are covered. Other
39 name: THC.
- 40 (32) Ethylamine analog of phencyclidine (7455). Some trade or
41 other names: N-Ethyl-1-phenylcyclohexylamine;
42 (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl)



- 1 ethylamine; cyclohexamine; PCE.
 2 (33) Pyrrolidine analog of phencyclidine (7458). Some trade or
 3 other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCP_y; PHP.
 4 (34) Thiophene analog of phencyclidine (7470). Some trade or
 5 other names: 1-(1-(2-thienyl) cyclohexyl) piperidine; 2-Thienyl
 6 Analog of Phencyclidine; TPCP.
 7 ~~(35)~~ Synthetic drugs (as defined in IC 35-31.5-2-321).
 8 ~~(36)~~ (35) Salvia divinorum or salvinorin A, including:
 9 (A) all parts of the plant that are classified botanically as salvia
 10 divinorum, whether growing or not;
 11 (B) the seeds of the plant;
 12 (C) any extract from any part of the plant; and
 13 (D) every compound, manufacture, salt, derivative, mixture, or
 14 preparation of the plant, its seeds, or extracts.
 15 ~~(37)~~ (36) 5-Methoxy-N,N-Dimethyltryptamine. Some trade or
 16 other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole;
 17 5-MeO-DMT.
 18 ~~(38)~~ (37) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).
 19 ~~(39)~~ (38) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).
 20 ~~(40)~~ (39) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C).
 21 ~~(41)~~ (40) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I).
 22 ~~(42)~~ (41) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl] ethanamine
 23 (2C-T-2).
 24 ~~(43)~~ (42) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine
 25 (2C-T-4).
 26 ~~(44)~~ (43) 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H).
 27 ~~(45)~~ (44) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N).
 28 ~~(46)~~ (45) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine
 29 (2C-P).
 30 (e) Depressants. Unless specifically excepted in a rule adopted by
 31 the board or unless listed in another schedule, any material, compound,
 32 mixture, or preparation which contains any quantity of the following
 33 substances having a depressant effect on the central nervous system,
 34 including its salts, isomers, and salts of isomers whenever the existence
 35 of such salts, isomers, and salts of isomers is possible within the
 36 specific chemical designation:
 37 Gamma-hydroxybutyric acid (other names include GHB;
 38 gamma-hydroxybutyrate; 4-hydroxybutanoic acid; sodium
 39 oxybate; sodium oxybutyrate) (2010)
 40 Mecloqualone (2572)
 41 Methaqualone (2565)
 42 (f) Stimulants. Unless specifically excepted or unless listed in



- 1 another schedule, any material, compound, mixture, or preparation that
2 contains any quantity of the following substances having a stimulant
3 effect on the central nervous system, including its salts, isomers, and
4 salts of isomers:
5 ([+/-] cis-4-methylaminorex (([+/-]cis-4,5-
6 dihydro-4-methyl-5-phenyl-2-oxazolamine) (1590)
7 Aminorex (1585). Other names: aminoxaphen;
8 2-amino-5-phenyl-2-oxazoline; or
9 4,5-dihydro-5-phenyl-2-oxazolamine.
10 Cathinone (1235). Some trade or other names:
11 2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone;
12 2-aminopropiophenone; and norephedrone.
13 Fenethylamine (1503).
14 N-Benzylpiperazine (7493). Other names: BZP; and
15 1-benzylpiperazine.
16 N-ethylamphetamine (1475).
17 Methcathinone (1237) Some other trade names:
18 2-Methylamino-1-Phenylpropan-1-one; Ephedrone;
19 Monomethylpropion; UR 1431.
20 N, N-dimethylamphetamine (1480). Other names: N,
21 N-alpha-trimethyl-benzeneethanamine; and N,
22 N-alpha-trimethylphenethylamine.
23 **(g) Synthetic drugs as defined in IC 35-31.5-2-321.**



COMMITTEE REPORT

Mr. Speaker: Your Committee on Public Health, to which was referred House Bill 1272, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill be amended as follows:

Page 2, line 2, after "the" insert "**agency with consultation from the**".

Page 2, line 2, reset in roman "board".

Page 2, line 2, after "shall" insert "**may**".

Page 2, line 3, before "agency" reset in roman "randomly".

Page 2, line 3, delete "agency may randomly".

Page 2, line 3, reset in roman "more than one".

Page 2, line 4, reset in roman "percent (1%) but less than ten percent (10%)".

Page 2, line 4, delete "up to five percent (5%)".

and when so amended that said bill do pass.

(Reference is to HB 1272 as introduced.)

KIRCHHOFER

Committee Vote: yeas 12, nays 0.

 HOUSE MOTION

Mr. Speaker: I move that House Bill 1272 be amended to read as follows:

Page 3, between lines 19 and 20, begin a new paragraph and insert:
 "SECTION 5. IC 25-27.5-5-2, AS AMENDED BY P.L.197-2011, SECTION 120, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2016]: Sec. 2. (a) A physician assistant must engage in a dependent practice with physician supervision. A physician assistant may perform, under the supervision of the supervising physician, the duties and responsibilities that are delegated by the supervising physician and that are within the supervising physician's scope of practice, including prescribing and dispensing drugs and medical devices. A patient may elect to be seen, examined, and treated by the supervising physician.

(b) If a physician assistant determines that a patient needs to be examined by a physician, the physician assistant shall immediately notify the supervising physician or physician designee.

EH 1272—LS 6628/DI 109



(c) If a physician assistant notifies the supervising physician that the physician should examine a patient, the supervising physician shall:

- (1) schedule an examination of the patient in a timely manner unless the patient declines; or
- (2) arrange for another physician to examine the patient.

(d) If a patient is subsequently examined by the supervising physician or another physician because of circumstances described in subsection (b) or (c), the visit must be considered as part of the same encounter except for in the instance of a medically appropriate referral.

(e) A supervising physician or physician assistant who does not comply with subsections (b) through (d) is subject to discipline under IC 25-1-9.

(f) A physician assistant's supervisory agreement with a supervising physician must:

- (1) be in writing;
- (2) include all the tasks delegated to the physician assistant by the supervising physician;
- (3) set forth the supervisory plans for the physician assistant, including the emergency procedures that the physician assistant must follow; and
- (4) specify the ~~name of the drug or drug classification being delegated to the physician assistant and the protocol the physician assistant shall follow in prescribing a drug.~~

(g) The physician shall submit the supervisory agreement to the board. The physician assistant may prescribe a drug under the supervisory agreement unless the board denies the supervisory agreement. Any amendment to the supervisory agreement must be resubmitted to the board, and the physician assistant may operate under any new prescriptive authority under the amended supervisory agreement unless the agreement has been denied by the board.

(h) A physician or a physician assistant who violates the supervisory agreement described in this section may be disciplined under IC 25-1-9."

Renumber all SECTIONS consecutively.

(Reference is to HB 1272 as printed January 22, 2016.)

DAVISSON



COMMITTEE REPORT

Madam President: The Senate Committee on Commerce & Technology, to which was referred House Bill No. 1272, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill DO PASS.

(Reference is to HB1272 as reprinted January 26, 2016.)

BUCK, Chairperson

Committee Vote: Yeas 8, Nays 0

